Protara Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 2.60% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2020-07-31
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.37%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.60%, a 1.96% increase from fiscal 2018.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.55%, a 22.01% increase from fiscal 2017.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 2.09%, a 44.14% increase from fiscal 2016.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 1.45%, a 17.61% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|
| 2019-12-31 | 2.60% 10-K · filed 2020-03-20 | ||
| 2019-06-30 | 2.37% 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | 2.37% 10-Q · filed 2020-05-13 | ||
| 2018-12-31 | 2.55% 10-K · filed 2020-03-20 | ||
| 2017-12-31 | 2.09% 10-K · filed 2019-03-13 | ||
| 2016-12-31 | 1.45% 10-K · filed 2019-03-13 | ||
| 2015-12-31 | 1.76% 10-K · filed 2018-03-14 | ||
| 2014-12-31 | 1.88% 10-K · filed 2017-03-16 | ||
| 2013-12-31 | 1.03% 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |